The Catalyst

Most Recent Posts

06.27.11 | By Kate Connors

Speaking at the BIO 2011 International Convention, Jeff Behrens from early-stage company Edimer Pharma discussed the many challenges that orphan drug developers confront in their quest to successfully treat a rare disease.

06.27.11 | By Kate Connors

Today kicks off the Biotechnology Industry Organization's 2011 International Convention. The four-day event is one of the biopharmaceutical research sector's largest gatherings and is sure to generate some interesting coverage.

06.24.11 | By Kate Connors

Yesterday, the Partnership for Safe Medicines - of which PhRMA is one of many members - held a congressional briefing to discuss the threat of rogue online pharmacies to patients in America.


The Institute of Medicine (IOM) released a new report this week looking at childhood obesity prevention policies. The report notes that, today, "almost 10 percent of infants and toddlers carry excess weight for their length, and slightly more than 20 percent of children between the ages of two and five are already overweight or obese.


We've said before in this blog, that the task of researching and developing new medicines is growing more difficult as the science and technology used in the hunt become more complex. That's why the effort to bring new, collaborative thinking to address scientific and medical challenges, as well as new resources to the work, is so critical to future success.


From the tornadoes that ripped through the Southeast and Central United States to the Japan earthquake and tsunami, the 2011 winter snowstorm and recent flooding along the Mississippi River, Rx Response has been busy tracking potential disruptions to the biopharmaceutical supply system.

06.22.11 | By Kate Connors

This week, the Kaiser Family Foundation released the results of a survey seeking to capture the public's opinions about HIV/AIDS.

06.21.11 | By Lorraine Egan

Earlier today, the Damon Runyon Cancer Research Foundation launched 'Accelerating Cancer Cures,' a new initiative that brings together PhRMA, some of the industry's leading companies, and partners in academia to address the critical shortage of new young physician-scientists choosing careers in research, while also advancing a translational research model that will play a key role in discovering tomorrow's cancer cures.

06.21.11 | By Kate Connors

Tomorrow, PhRMA and the U.S. Department of Commerce will convene a roundtable discussion on export opportunities for biopharmaceutical research companies, with a particular emphasis on emerging companies as they seek to build an infrastructure that allows for increased exports.


There was an interesting study released in Nature on efforts to use vaccines to fight cancer. There's a good overview of the study here.

06.17.11 | By Deborah Oswalt

I am pleased to announce that the Virginia Health Care Foundation (VHCF) presented PhRMA with our prestigious You "Rx"ceptional Award for its work with The Pharmacy Connection at our annual "Heroes in Health Care" ceremony on Tuesday, June 14. PhRMA and VHCF have collaborated over the last decade to provide $1 billion worth of free medicine to uninsured Virginians through The Pharmacy Connection.

06.17.11 | By Ken Thorpe

Throughout the world, chronic non-communicable diseases exert a tremendous economic and social burden. The recent World Health Organization Status Report on Non-communicable Diseases (NCDs) estimates that 63% or 36 million of the 57 million deaths that occurred globally in 2008 were attributable to NCDs , primarily cardiovascular diseases, cancers, diabetes and chronic lung diseases.

06.16.11 | By Kate Connors

Each year, Ernst & Young publishes a report about the global biotechnology sector. In this year's report, which they recently released, they comment about the notable fact that it has been 25 years since they began the report - how far a once-nascent field has evolved in that short amount of time!

It's a hefty read, but they included a really worthwhile two-page chart that details the state of the sector.

06.16.11 | By Kate Connors
In recent months, there has been a good deal of discussion about R&D productivity, with references, for example, to a slight decline in the average number of new medicines approved by the FDA in recent years. This, of course, is at a time when we continue to see record investment in R&D, with America's biopharmaceutical research companies last year investing $67.4 billion in the discovery and development of new medicines.